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INTRODUCTION
To improve the debilitating features of Parkinson disease
(PD), surgery was the main frame for the patients suffering
from the disease in the early 19th century.1 Lesions of the
thalamus and pallidum leads to debilitating tremor and
rigidity.2,3 With the advent of oral Levodopa therapy, a
drastic reduction in the number of surgeries performed on
PD patients with additional advantage of improving
akinesia, was observed. However, after a few years
complications of chronic levodopa intake, mainly
dyskinesias and on-off fluctuations, started to raise other
challenges.4,5
This led to resuming surgical approaches such as ablation
of globus pallidus. Pallidotomies seemed to have a good
effect on contralateral tremor, rigidity, and dyskinesias6-9
but it is accompanied with high rates of permanent
adverse effects.10-12 This prompted clinicians to search for
a better target. There has been a rising interest in STN as
a new target considering its inhibitory function within the
basal ganglia loops.
Development of high frequency deep brain stimulation
(DBS) in neurosurgery provided a better alternative for
physicians to alleviate movement disorder.13,14 This
procedure was performed on different nuclei.15,16 In
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ABSTRACT
Introduction: To improve the debilitating features of Parkinson disease (PD) various medical and surgical approaches are
available. Subthalamic nucleus deep brain stimulation (STN-DBS) was appeared to be a promising method during last two
decades. This study aimed to evaluate early motor outcomes of this procedure in one of the first trials of Iranian patients.
Materials and Methods: Thirty-seven patients with advanced Parkinson disease, unresponsive to common medical
agents, underwent bilateral STN-DBS. For assessment of motor function parameters “Unified Parkinson Disease Rating
Scale III” (UPDRS III) was used. We compared total scores and sub-scores in three categories performed as 1) preoperative
off-medication, 2) preoperative on-medication and 3) six months postoperative on medication. Reduction in drug
consumption was assessed considering administered doses of l-dopa before and after surgery in stable states. Results:
Twenty six males and 10 females with mean age of 50 years were evaluated (one patient expired before 6-month follow-
up). Mean total scores of UPDRSIII were 5.2±54.52, 2.88±18.22 and 3±12.8 in the three categories, respectively
(p=0.003). PostHoc analyses showed significant improvement among all categories. Analysis of sub-scores also revealed
significant amelioration in rigidity, action tremor, hand movement, leg agility, finger tap and rapid alternating movement in
on-medication phases of pre- and post-operation (all with p<0.01). Mean dosage administered of l-dopa were224±1296
mg/d and 174±782 mg/d before and after surgery, significant decline was observed. (p<0.001). Conclusion: Our results
indicated that bitemporal STN-DBS can result in significant short-term improvement of the motor symptoms especially in
debilitating symptoms such as rigidity and tremor in advanced PD. It also accompanies with remarkable reduction in the
needed doses of drugs. The findings support other studies with similar follow-up interval; however, continuous evaluations
are needed for long-lasting results.
Pak J Neurol Sci 2010; 5(1): 10-14
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1993, Benabid performed Subthalamic nucleus deep
brain stimulation (STN-DBS) in a patient with advanced
PD.17 Subsequently many centers followed and now the
procedure is widely accepted as a treatment for patients
unresponsive to medical agents. Comparing to previous
procedures it is reversible, less invasive and can be
performed bilaterally.19-23
However, short and long term follow-up data are needed
to evaluate the efficacy and complications of STN-DBS.
Our centre was the first one in Iran which applied the
procedure for advanced Parkinson disease. Here we will
report 6-month follow-up of patients regarding their motor
function and drug administration.
MATERIAL AND METHODS
Sample
Thirty seven patients with severe Parkinson disease were
enrolled between 2004 and 2007. They were referred to
Rasoul Akram Hospital affiliated to Iran University of
Medical Sciences (IUMS), where STN-DBS procedure for
treatment of PD performed in Iran. 
Individuals were included in case of having >30%
improvement in levodopa challenge test. We excluded
patients with significant psychiatric or behavioural illness,
any focal brain abnormalities on MRI, severe medical
problems and general contraindications for surgery such
as severe hypertension or coagulopathy. The study was
approved by our Institutional Review Board and written
informed consents were provided by all subjects.
Surgery
Streotactic MRI imaging was applied to provide direct
visualisation of subthalamic nucleus. Tetrapolar electrodes
were used simultaneously or subsequently for
electrophysiological exploration. The process was
performed under local anesthesia and a trained
neurologist assessed clinical response to DBS in the
operating room. After ascertaining the optimal track, the
corresponding microelectrode was replaced by a chronic
lead. We placed subcutaneous pulse generator after
several days under general anesthesia. During the next
week programming was done by the neurologist.   
Clinical evaluation
Motor performance was evaluated using UPDRS part III
including items for speech, facial expression, resting
tremor, action tremor, rigidity, finger tap, hand movement,
rapid alternating movement, leg agility, arising from chair,
gait, bradykinesia and posture stability each with a score
between 0 to 4. Lower scores reflect better performances.
Preoperative UPDRSIII assessments were conducted in the
on- and off-medication state. Postoperative scores were
evaluated only in the stimulator-on condition with
medication at 6 months of follow-up, because all patients
kept their st imulators on and using medication
continuously. 
Medication
A stable level of l-dopa maintained for at least 2 months
prior to surgery was considered as preoperative
medication. For postoperative measurement, the
administered dose of the drug at 6 months after surgery
was taken into account. No one in our study had off-
medication state after surgery.
Statistical analysis
Descriptive analysis of the data is presented as means
and standard deviations. UPDRS III total score and items'
sub-scores in two pre-operative and 6 - month follow-up
measurements were compared using repeated-measure
ANOVA. For analysing dichotomous evaluations, like drug
doses before and after surgery paired t-test was applied. A
p-value <0.05 is considered to be statistically significant.
All data have been analyzed by SPSS version 15.
RESULTS
Thirty seven patients with advanced Parkinson disease
underwent STN-DBS surgery. One of them died of
myocardial infarction before discharge. Rests of the
patients were included in the study to evaluate 6-month
follow-up. Mean age of patients was 50 ± 3 ranging from
32 to 72 years. The mean duration from beginning of the
symptoms till the time of the surgery was 11.28 ± 1.88
years. Bilateral approach of STN DBS was applied for all
patients.
Pre-operative UPDRS III scores of off- and on-medication
measurements were 54.52  ± 5.4 and 18.22 ± 2.88,
respectively. Postoperative score yielded 12.8±3.14 that
showed significant difference comparing with both
preoperative scores (p<0.001). Analysis of UPDRS III sub-
scores in two preoperative measurements revealed
signif icant improvement in al l  i tems after l-dopa
consumption (p<0.05). Comparison of findings from two
on-medication phases revealed performing DBS led to
significant alleviation in rigidity, action tremor, finger tap,
rapid alternating hand movement and body bradykinesia
(Table 1). 
Complication
Neurostimulation parameters of lead coordinates are
available in another report of technical issues of the
procedure performed in Iran. There was no implant-related
complication in any of our patients.
Medication
Regarding the medication used, mean L-dopa equivalent
doses showed significant decline from 1296 ± 224 mg/d
before surgery to 783 ± 87 mg/d after DBS (p<0.001). 
DISCUSSION
As a target of ablation therapy, the globus pallidius (GP)
has for a long time been the standard in the management
of parkinsonian syndrome.6-9 However, serious adverse
effects, such as visual impairment and behavioral and
cognitive disturbances necessitate probing for more
effective procedures.10-12 Introduction of deep brain
stimulation (DBS), made it possible to reduce many of
these complications as it is non-destructive and reversible.
Stimulation of STN appeared to be more effective than GP
because of its smaller size and more homogenous
structure.24
We have evaluated the short term results of bilateral STN-
DPS on motor condition and drug consumption in
advanced Parkinson cases. The study benefited from
acceptable sample size37 comparing with other studies
that had enrolled 5 to 50 patients. The age range of
individuals in the study was consistent with advised
suitable one for undergoing the procedure because people
over 70-75 do not yield favorable response.
A significant effect was observed on motor function at 6
months follow-up. This improvement was calculated as
over 60% in total score of UPDRS III and in items related
to rigidity, bradykinesia, action tremor, finger tap, rapid
and alternating hand movement as well. All of individuals
were assessed on medication with the stimulator on after
surgery. We also observed a considerable reduction in the
frequency and severity of motor fluctuations, the symptom
contributes to major preoperative functional limitations.
This favorable improvement in advanced disease is crucial
for the patients and often represents the main objective of
the procedure.
Considerable lower need for anti-parkinsonian medication
by 40% while using the stimulator was another positive
finding that, consequently, can result in antidyskinetic
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TABLE 1. Scores and sub-scores of UPDRS III in three measurements of preoperative off-medication, preoperative on-medication
and six months postoperative on medication.
Preoperation  Preoperation Postoperation P value*
off-medication on-medicaion on-medication
UPDRSIII (total) 54.52±5.4 18.22±2.88 12.8±3.14 0.000
Speech 1.94±0.28 1.11±0.24 1.05±0.28 0.6
Facial expression 1.91±0.2 1.11±0.14 0.97±0.14 0.09
Resting tremor 8.36±1.44 1.52±0.64 0.83±0.46 0.05
Action tremor 3.05±0.62 0.55±0.24 0.25±0.16 0.02
Rigidity 11.02±1.28 3.44±0.88 1.41±0.68 0.000
Finger tap 4.66±0.62 1.66±0.42 1.25±0.52 0.02
Hand movement 4.02±0.62 1.41±0.48 1.02±0.48 0.004
Rapid alternating movement 3.88±0.68 0.83±0.34 0.55±0.34 0.03
Leg agility 5.02±0.68 2.8±0.56 2.25±0.66 0.07
Arising from chair 1.8±0.4 0.19±0.14 0.16±0.16 0.71
Posture 1.97±0.24 0.83±0.18 0.75±0.2 0.41
Gait 2.13±0.32 0.75±0.22 0.63±0.24 0.25
Postural stability 2.08±0.32 1.02±0.2 1±0.22 0.74
Body bradykinesia 2.58±0.32 0.91±0.24 0.63±0.24 0.02
Values are expressed as means±2SEM
*p value refers to the comparison between preoperation, on-medicaion and postoperation, on-medication conditions.
effect. The average medication reduction in the prior
studies was reported 57.8%.20-24
As mentioned in other studies it was not possible to blind
investigators or patients. They often became aware of the
on/off status of the stimulation because of the symptom
relief or because of symptoms that occurred at the onset
of stimulation, like parasthesia. Severe complications of
the procedure are infrequent in reported surveys. The
most common problem is, though mostly transient,
deterioration of the patients' psychiatric state. Similar
observations have already been reported for ablative
operations as well as for stimulation procedures in both
the GPi and STN. Therefore, careful patient selection and
preoperative neuropsychological testing over an extended
period are of utmost importance.
Finally, our study along with other studies support the
beneficial outcome of STN-DBS in improving parkinsonian
motor signs and reducing medication and supports its
utilization in selected target for the treatment advanced
stages of the disease. However, long term follow-ups are
needed for complete assessment.
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